Business Wire

TPx selects ADVA for edge device innovation

Share

ADVA (FSE: ADV) today announced that TPx has selected its Ensemble software as the basis of a new universal customer premises (uCPE) platform. The managed services provider will harness the high-performance virtualization suite to power its ReadyEdge uCPE offering, enabling it to quickly and easily roll out and manage multiple dynamic virtual network functions (VNFs) for its enterprise customers. Services such as managed SD-WAN and firewall products will be deployed on a single dedicated hardware device at customer sites.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190827005495/en/

James Buchanan, GM, Edge Cloud, ADVA (Photo: Business Wire)

James Buchanan, GM, Edge Cloud, ADVA (Photo: Business Wire)

“With this solution, TPx will consolidate a number of appliances into a single service platform based on an open white box uCPE architecture that is reliable, scalable and proven in the field. We’ll be able to support today’s services such as SD-WAN and firewalls at more flexible cost points than we can with dedicated appliances,” said Jared Martin, VP, MSx managed services, TPx. “Leveraging the ADVA Ensemble suite also enables us to offer our customers new services delivered dynamically and on demand, without having to change the hardware. That gives them the agility and responsiveness they need.”

TPx currently delivers unified communications, managed IT, network security and network connectivity to over 53,000 customer locations. With ADVA’s Ensemble software and ReadyEdge uCPE platform, TPx clients can look forward to an enhanced customer experience, faster provisioning and simpler deployments, as well as quicker reconfiguration of service changes. The TPx managed hosting service leverages a number of products from the Ensemble software suite, including Ensemble Orchestrator, Ensemble Virtualization Director and Ensemble Connector. It also offers access to the Ensemble Harmony Ecosystem, the market’s largest set of onboarded VNFs and virtual servers.

“Service providers and their customers are embracing cloud technologies for networking. They need openness and choice, but also a solution optimized for the far edge of the network. We answer that need with open technology that includes a full set of field-tested operational features, supporting ease of deployment at a global scale,” commented James Buchanan, GM, Edge Cloud, ADVA. “We’ve been chosen to give a crucial competitive edge to TPx’s enterprise customers. The power to harness new best-of-breed software applications without changing network equipment opens the door to a host of new opportunities.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com

About TPx

TPx is the nation’s premier managed services provider, delivering unified communications, managed IT and network connectivity to over 50,000 customer locations across the country. Our proven, industry-leading customer service focus has powered more than 17 years of uninterrupted growth for TPx – all driven by earned referral, not advertising. We’ve evolved as technologies and marketplaces began to change so that we could always be there for our customers. We’re able to put together the comprehensive solutions they need, with guaranteed performance, so that they can compete, grow and focus on managing their businesses, confident that we are there for them. www.tpx.com

Published by:

ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CESTPress release

The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na

TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CESTPress release

TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CESTPress release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio

JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine

U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva